<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>2004</number>
    <updateDate>2022-11-01T13:50:51Z</updateDate>
    <updateDateIncludingText>2022-11-01T13:50:51Z</updateDateIncludingText>
    <originChamber>Senate</originChamber>
    <type>S</type>
    <introducedDate>2019-06-27</introducedDate>
    <congress>116</congress>
    <committees>
      <item>
        <systemCode>ssfi00</systemCode>
        <name>Finance Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2019-06-27T15:34:37Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>Emergency Access to Insulin Act of 2019</title>
        <congress>116</congress>
        <number>4010</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2019-07-26</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Identical bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2019-06-27</actionDate>
        <committees>
          <item>
            <systemCode>ssfi00</systemCode>
            <name>Finance Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Finance.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2019-06-27</actionDate>
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>S001203</bioguideId>
        <fullName>Sen. Smith, Tina [D-MN]</fullName>
        <firstName>Tina</firstName>
        <lastName>Smith</lastName>
        <party>D</party>
        <state>MN</state>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>C001096</bioguideId>
        <fullName>Sen. Cramer, Kevin [R-ND]</fullName>
        <firstName>Kevin</firstName>
        <lastName>Cramer</lastName>
        <party>R</party>
        <state>ND</state>
        <sponsorshipDate>2019-06-27</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Accounting and auditing</name>
        </item>
        <item>
          <name>Business ethics</name>
        </item>
        <item>
          <name>Business records</name>
        </item>
        <item>
          <name>Competition and antitrust</name>
        </item>
        <item>
          <name>Congressional oversight</name>
        </item>
        <item>
          <name>Digestive and metabolic diseases</name>
        </item>
        <item>
          <name>Government information and archives</name>
        </item>
        <item>
          <name>Health care costs and insurance</name>
        </item>
        <item>
          <name>Health care coverage and access</name>
        </item>
        <item>
          <name>Health information and medical records</name>
        </item>
        <item>
          <name>Health programs administration and funding</name>
        </item>
        <item>
          <name>Health technology, devices, supplies</name>
        </item>
        <item>
          <name>Indian social and development programs</name>
        </item>
        <item>
          <name>Inflation and prices</name>
        </item>
        <item>
          <name>Intergovernmental relations</name>
        </item>
        <item>
          <name>Licensing and registrations</name>
        </item>
        <item>
          <name>Manufacturing</name>
        </item>
        <item>
          <name>Minority health</name>
        </item>
        <item>
          <name>Performance measurement</name>
        </item>
        <item>
          <name>Prescription drugs</name>
        </item>
        <item>
          <name>Public contracts and procurement</name>
        </item>
        <item>
          <name>Public-private cooperation</name>
        </item>
        <item>
          <name>Retail and wholesale trades</name>
        </item>
        <item>
          <name>Sales and excise taxes</name>
        </item>
        <item>
          <name>State and local finance</name>
        </item>
        <item>
          <name>State and local government operations</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2019-06-27</actionDate>
        <actionDesc>Introduced in Senate</actionDesc>
        <updateDate>2020-10-20T15:53:17Z</updateDate>
        <text><![CDATA[ <p><b>Emergency Access to Insulin Act of 2019</b></p> <p>This bill reduces the marketing exclusivity period for biological drug products from 12 to 7 years and establishes policies and programs designed to increase access to prescription insulin. Specifically, the bill requires the Centers for Disease Control and Prevention to award grants to states to create insulin card programs, which provide uninsured or underinsured individuals with insulin at no cost for specified time periods. Payments for insulin prescriptions made through the program must count toward an underinsured individual&rsquo;s health plan deductible. Further, the Department of Health and Human Services (HHS) must collect annual fees from insulin manufacturers, based on each manufacturer&rsquo;s market share, equal to the total estimated expenditures under the insulin grants program.</p> <p>Subject to certain exceptions, the bill also establishes an excise tax on insulin manufacturers when the price of an insulin product spikes. The tax amount is a specified percentage of the revenue a manufacturer received as a result of the price spike. The tax amount increases in tiers based on the percentage of the price spike for that product.</p> ]]></text>
      </summary>
    </summaries>
    <title>Emergency Access to Insulin Act of 2019</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>Emergency Access to Insulin Act of 2019</title>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <title>Emergency Access to Insulin Act of 2019</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>A bill to amend the Public Health Service Act to establish insulin assistance programs, and for other purposes.</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in Senate</type>
        <date>2019-06-27T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-116s2004is/xml/BILLS-116s2004is.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2019-06-27</actionDate>
      <text>Read twice and referred to the Committee on Finance.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
